[The survival analysis of metastatic prostate cancer].
OBJECTIVE
To analyze the clinical and pathological informations of metastatic prostate cancer patients to find the predictive factors of the survival.


METHODS
To filter 364 cases of metastatic prostate cancer in the 940 cases of prostate cancer that were treated in Cancer Hospital Fudan University in Shanghai from March 1998 to June 2009, the cases had hormonal therapy and full clinical and pathological records. All the 364 cases were followed up and the clinical and pathological informations were analyzed, to find the predictive factors that related to the prognosis. Statistic software SPSS 15.0 was used for analysis. Cumulative survival was analyzed by the method of Kaplan-Meier. Cox regression was used for univariate and multivariate analysis. Log-rank method was used for the significance test.


RESULTS
The last follow-up date was 30th June 2009 and the median follow-up time was 24 months. At the final follow-up, 240 cases were alive, 109 cases were dead and 15 cases were lost to follow up. The median survival time of metastatic prostate cancer was 64 months, and the one-year, two-year, three-year, four-year, five-year survival rate was 92%, 78%, 66%, 60%, 54%. The univariate analysis indicated that Gleason score (P = 0.033), clinical stage (P < 0.001), the effectiveness of hormonal therapy (P < 0.001), the prostate specific antigen (PSA) nadir during hormonal therapy (P < 0.001) and the time from the start of hormonal therapy to the PSA nadir (P = 0.002) were predictive factors for the survival time of metastatic prostate cancer. The multivariate analysis indicated that the PSA nadir during hormonal therapy (P < 0.001) and the time from the start of hormonal therapy to the PSA nadir (P < 0.001) were independent factors that predict the survival time of metastatic prostate cancer.


CONCLUSIONS
The PSA nadir during hormonal therapy and the time from the start of hormonal therapy to the PSA nadir are independent factors that predict the survival time of metastatic prostate cancer.
Department of Urology, Cancer Hospital, Fudan University, Shanghai 200032, China.
Chun-Guang
CG
Ma
Ding-Wei
DW
Ye
Xu-Dong
XD
Yao
Shi-Lin
SL
Zhang
Bo
B
Dai
Hai-Liang
HL
Zhang
Yao
Y
Zhu
Yi-Jun
YJ
Shen
Yi-Ping
YP
Zhu
Guo-Hai
GH
Shi
Xiao-Jian
XJ
Qin
Guo-Wen
GW
Lin
Wen-Jun
WJ
Xiao
Li-Feng
LF
Yang
Bo-Shuai
BS
Yang
Da-Long
DL
Cao
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000628:therapy*; D012189:Retrospective Studies